Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Perspective Therapeutics ( (CATX) ) has shared an update.
On February 2, 2026, Perspective Therapeutics, Inc. entered into an underwriting agreement for a previously announced underwritten offering of 39,576,088 common shares and pre-funded warrants to purchase 6,598,046 shares, priced at $3.79 per share and $3.789 per pre-funded warrant, respectively; the transaction, led by Piper Sandler and UBS Securities, closed on February 3, 2026 and generated approximately $175 million in gross proceeds. The company plans to deploy the net proceeds to advance clinical development of its radiopharmaceutical pipeline, expand and upgrade its manufacturing infrastructure, fund working capital and other general corporate needs, and potentially pursue acquisitions or licensing of complementary assets, moves that are expected to bolster its operational capacity and financial flexibility as it seeks to strengthen its position in the oncology theranostics market.
The most recent analyst rating on (CATX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Perspective Therapeutics stock, see the CATX Stock Forecast page.
Spark’s Take on CATX Stock
According to Spark, TipRanks’ AI Analyst, CATX is a Neutral.
The score is held back primarily by very weak financial performance (large losses and significant cash burn despite minimal revenue). Offsetting factors include a constructive technical uptrend and positive pipeline/manufacturing corporate updates that can support sentiment and optionality, while valuation remains difficult to assess favorably due to negative earnings and no dividend.
To see Spark’s full report on CATX stock, click here.
More about Perspective Therapeutics
Perspective Therapeutics, Inc., listed on NYSE American under the symbol CATX, is a radiopharmaceutical development company pioneering advanced cancer treatments using proprietary technology based on the alpha-emitting isotope 212Pb. The company pairs targeted radiotherapies with complementary imaging diagnostics in a theranostic approach designed to visualize tumors and then treat them, with current Phase 1/2a programs in neuroendocrine tumors (VMT-α-NET), melanoma (VMT01) and solid tumors (PSV359), supported by a growing network of 212Pb-enabled finishing facilities for clinical and eventual commercial supply.
Average Trading Volume: 3,288,652
Technical Sentiment Signal: Buy
Current Market Cap: $281.7M
See more insights into CATX stock on TipRanks’ Stock Analysis page.